Andrew is a seasoned European commercialisation strategist with deep expertise in helping global biopharma companies bring rare-disease and specialty therapies to market across Europe. With more than 30 years of experience and focus spanning early-access programmes, pricing and reimbursement strategy, real-world evidence generation, rare-disease launch models, and complex cross-border distribution, Andrew has supported numerous companies in accelerating access for patients with high-unmet-need conditions.

​

He is particularly recognised for his command of Europe’s fragmented early-access frameworks used for rare-disease and specialty products. Andrew blends regulatory fluency with hands-on commercial execution, guiding companies through orphan-drug commercialisation, distributor selection, supply-chain design, and go-to-market strategy tailored specifically for small, often-heterogeneous patient populations.

​

Andrew’s advisory practice is rooted in providing pragmatic, actionable pathways for Pharma/Biotech entering Europe for the first time , particularly those developing ultra-rare, rare, or highly specialised therapies that require bespoke access, funding, and distribution solutions. His work spans programmes ranging from early-access design and paid-for unlicensed supply to RWE frameworks and full EU launch planning. He is known for simplifying complexity, anticipating obstacles, and delivering clear, commercially sound routes that maximise the probability of patient access across Europe.